Myeloproliferative neoplasms, version 2.2018 featured Updates to the NCCN guidelines

Ruben A. Mesa, Catriona Jamieson, Ravi Bhatia, Michael W. Deininger, Christopher D. Fletcher, Aaron T. Gerds, Ivana Gojo, Jason Gotlib, Krishna Gundabolu, Gabriela Hobbs, Brandon McMahon, Sanjay R. Mohan, Stephen Oh, Eric Padron, Nikolaos Papadantonakis, Philip Pancari, Nikolai Podoltsev, Raajit Rampal, Erik Ranheim, Vishnu Reddy & 11 others Lindsay A.M. Rein, Bart Scott, David S. Snyder, Brady L. Stein, Moshe Talpaz, Srdan Verstovsek, Martha Wadleigh, Eunice S. Wang, Mary Anne Bergman, Kristina M. Gregory, Hema Sundar

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thrombohemorrhagic complications and a high risk of transformation to MF and acute myeloid leukemia. The diagnosis and management of PV and ET has evolved since the identification of mutations implicated in their pathogenesis. These NCCN Guideline Insights discuss the recommendations outlined in the NCCN Guidelines for the risk stratification, treatment, and special considerations for the management of PV and ET.

Original languageEnglish (US)
Pages (from-to)1193-1207
Number of pages15
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume15
Issue number10
DOIs
StatePublished - Oct 1 2017

Fingerprint

Essential Thrombocythemia
Polycythemia Vera
Guidelines
Primary Myelofibrosis
Neoplasms
Hematopoietic System
Acute Myeloid Leukemia
Mutation

ASJC Scopus subject areas

  • Oncology

Cite this

Mesa, R. A., Jamieson, C., Bhatia, R., Deininger, M. W., Fletcher, C. D., Gerds, A. T., ... Sundar, H. (2017). Myeloproliferative neoplasms, version 2.2018 featured Updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 15(10), 1193-1207. https://doi.org/10.6004/jnccn.2017.0157

Myeloproliferative neoplasms, version 2.2018 featured Updates to the NCCN guidelines. / Mesa, Ruben A.; Jamieson, Catriona; Bhatia, Ravi; Deininger, Michael W.; Fletcher, Christopher D.; Gerds, Aaron T.; Gojo, Ivana; Gotlib, Jason; Gundabolu, Krishna; Hobbs, Gabriela; McMahon, Brandon; Mohan, Sanjay R.; Oh, Stephen; Padron, Eric; Papadantonakis, Nikolaos; Pancari, Philip; Podoltsev, Nikolai; Rampal, Raajit; Ranheim, Erik; Reddy, Vishnu; Rein, Lindsay A.M.; Scott, Bart; Snyder, David S.; Stein, Brady L.; Talpaz, Moshe; Verstovsek, Srdan; Wadleigh, Martha; Wang, Eunice S.; Bergman, Mary Anne; Gregory, Kristina M.; Sundar, Hema.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 15, No. 10, 01.10.2017, p. 1193-1207.

Research output: Contribution to journalReview article

Mesa, RA, Jamieson, C, Bhatia, R, Deininger, MW, Fletcher, CD, Gerds, AT, Gojo, I, Gotlib, J, Gundabolu, K, Hobbs, G, McMahon, B, Mohan, SR, Oh, S, Padron, E, Papadantonakis, N, Pancari, P, Podoltsev, N, Rampal, R, Ranheim, E, Reddy, V, Rein, LAM, Scott, B, Snyder, DS, Stein, BL, Talpaz, M, Verstovsek, S, Wadleigh, M, Wang, ES, Bergman, MA, Gregory, KM & Sundar, H 2017, 'Myeloproliferative neoplasms, version 2.2018 featured Updates to the NCCN guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 15, no. 10, pp. 1193-1207. https://doi.org/10.6004/jnccn.2017.0157
Mesa, Ruben A. ; Jamieson, Catriona ; Bhatia, Ravi ; Deininger, Michael W. ; Fletcher, Christopher D. ; Gerds, Aaron T. ; Gojo, Ivana ; Gotlib, Jason ; Gundabolu, Krishna ; Hobbs, Gabriela ; McMahon, Brandon ; Mohan, Sanjay R. ; Oh, Stephen ; Padron, Eric ; Papadantonakis, Nikolaos ; Pancari, Philip ; Podoltsev, Nikolai ; Rampal, Raajit ; Ranheim, Erik ; Reddy, Vishnu ; Rein, Lindsay A.M. ; Scott, Bart ; Snyder, David S. ; Stein, Brady L. ; Talpaz, Moshe ; Verstovsek, Srdan ; Wadleigh, Martha ; Wang, Eunice S. ; Bergman, Mary Anne ; Gregory, Kristina M. ; Sundar, Hema. / Myeloproliferative neoplasms, version 2.2018 featured Updates to the NCCN guidelines. In: JNCCN Journal of the National Comprehensive Cancer Network. 2017 ; Vol. 15, No. 10. pp. 1193-1207.
@article{78d81c53fc3040b9b5809230dd117ed7,
title = "Myeloproliferative neoplasms, version 2.2018 featured Updates to the NCCN guidelines",
abstract = "Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thrombohemorrhagic complications and a high risk of transformation to MF and acute myeloid leukemia. The diagnosis and management of PV and ET has evolved since the identification of mutations implicated in their pathogenesis. These NCCN Guideline Insights discuss the recommendations outlined in the NCCN Guidelines for the risk stratification, treatment, and special considerations for the management of PV and ET.",
author = "Mesa, {Ruben A.} and Catriona Jamieson and Ravi Bhatia and Deininger, {Michael W.} and Fletcher, {Christopher D.} and Gerds, {Aaron T.} and Ivana Gojo and Jason Gotlib and Krishna Gundabolu and Gabriela Hobbs and Brandon McMahon and Mohan, {Sanjay R.} and Stephen Oh and Eric Padron and Nikolaos Papadantonakis and Philip Pancari and Nikolai Podoltsev and Raajit Rampal and Erik Ranheim and Vishnu Reddy and Rein, {Lindsay A.M.} and Bart Scott and Snyder, {David S.} and Stein, {Brady L.} and Moshe Talpaz and Srdan Verstovsek and Martha Wadleigh and Wang, {Eunice S.} and Bergman, {Mary Anne} and Gregory, {Kristina M.} and Hema Sundar",
year = "2017",
month = "10",
day = "1",
doi = "10.6004/jnccn.2017.0157",
language = "English (US)",
volume = "15",
pages = "1193--1207",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "10",

}

TY - JOUR

T1 - Myeloproliferative neoplasms, version 2.2018 featured Updates to the NCCN guidelines

AU - Mesa, Ruben A.

AU - Jamieson, Catriona

AU - Bhatia, Ravi

AU - Deininger, Michael W.

AU - Fletcher, Christopher D.

AU - Gerds, Aaron T.

AU - Gojo, Ivana

AU - Gotlib, Jason

AU - Gundabolu, Krishna

AU - Hobbs, Gabriela

AU - McMahon, Brandon

AU - Mohan, Sanjay R.

AU - Oh, Stephen

AU - Padron, Eric

AU - Papadantonakis, Nikolaos

AU - Pancari, Philip

AU - Podoltsev, Nikolai

AU - Rampal, Raajit

AU - Ranheim, Erik

AU - Reddy, Vishnu

AU - Rein, Lindsay A.M.

AU - Scott, Bart

AU - Snyder, David S.

AU - Stein, Brady L.

AU - Talpaz, Moshe

AU - Verstovsek, Srdan

AU - Wadleigh, Martha

AU - Wang, Eunice S.

AU - Bergman, Mary Anne

AU - Gregory, Kristina M.

AU - Sundar, Hema

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thrombohemorrhagic complications and a high risk of transformation to MF and acute myeloid leukemia. The diagnosis and management of PV and ET has evolved since the identification of mutations implicated in their pathogenesis. These NCCN Guideline Insights discuss the recommendations outlined in the NCCN Guidelines for the risk stratification, treatment, and special considerations for the management of PV and ET.

AB - Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thrombohemorrhagic complications and a high risk of transformation to MF and acute myeloid leukemia. The diagnosis and management of PV and ET has evolved since the identification of mutations implicated in their pathogenesis. These NCCN Guideline Insights discuss the recommendations outlined in the NCCN Guidelines for the risk stratification, treatment, and special considerations for the management of PV and ET.

UR - http://www.scopus.com/inward/record.url?scp=85030841097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030841097&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2017.0157

DO - 10.6004/jnccn.2017.0157

M3 - Review article

VL - 15

SP - 1193

EP - 1207

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 10

ER -